Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 – News Description

In theglobal stem cells marketa sizeable proportion of companies are trying to garner investments from organizations based overseas. This is one of the strategies leveraged by them to grow their market share. Further, they are also forging partnerships with pharmaceutical organizations to up revenues.

In addition, companies in the global stem cells market are pouring money into expansion through multidisciplinary and multi-sector collaboration for large scale production of high quality pluripotent and differentiated cells. The market, at present, is characterized by a diverse product portfolio, which is expected to up competition, and eventually growth in the market.

Some of the key players operating in the global stem cells market areSTEMCELL Technologies Inc., Astellas Pharma Inc., Cellular Engineering Technologies Inc., BioTime Inc., Takara Bio Inc., U.S. Stem Cell, Inc., BrainStorm Cell Therapeutics Inc., Cytori Therapeutics, Inc., Osiris Therapeutics, Inc., and Caladrius Biosciences, Inc.

As per a report by Transparency Market Research, the global market for stem cells is expected to register a healthy CAGR of 13.8% during the period from 2017 to 2025 to become worth US$270.5 bn by 2025.

Request Sample of Stem Cells Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=132

Depending upon the type of products, the global stem cell market can be divided into adult stem cells, human embryonic stem cells, induced pluripotent stem cells, etc. Of them, the segment of adult stem cells accounts for a leading share in the market. This is because of their ability to generate trillions of specialized cells which may lower the risks of rejection and repair tissue damage.

Depending upon geography, the key segments of the global stem cells market are North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. At present, North America dominates the market because of the substantial investments in the field, impressive economic growth, rising instances of target chronic diseases, and technological progress. As per the TMR report, the market in North America will likely retain its dominant share in the near future to become worth US$167.33 bn by 2025.

Investments in Research Drives Market

Constant thrust on research to broaden the utility scope of associated products is at the forefront of driving growth in the global stem cells market. Such research projects have generated various possibilities of different clinical applications of these cells, to usher in new treatments for diseases.

Request for a Discount on Stem Cells Market Report

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=132

Since cellular therapies are considered the next major step in transforming healthcare, companies are expanding their cellular therapy portfolio to include a range of ailments such as Parkinsons disease, type 1 diabetes, spinal cord injury, Alzheimers disease, etc.

The growing prevalence of chronic diseases and increasing investments of pharmaceutical and biopharmaceutical companies in stem cell research are the key driving factors for the stem cells therapeutics market. The growing number of stem cell donors, improved stem cell banking facilities, and increasing research and development are other crucial factors serving to propel the market, explains the lead analyst of the report.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

ContactTransparency Market ResearchState Tower,90 State Street,Suite 700,Albany NY 12207United StatesTel:+1-518-618-1030USA Canada Toll Free:866-552-3453Email:[emailprotected]Website:http://www.transparencymarketresearch.comResearch Blog:https://theglobalhealthnews.com/

Original post:
Stem Cells Market to a Revenue Opportunity of US$270.5 bn During the Period from 2025 - News Description

Stem cell Therapy Market 2019-2027| Business Scope and Investment Analysis By MEDIPOST, PHARMICELL Co., Ltd, Holostem Terapie Avanzate Srl, Mesoblast…

Global Stem cell therapy Market report offers meticulous investigation of current scenario of the global market, which considers numerous market dynamics. This market report identifies and analyses the emerging trends along with key drivers, challenges and opportunities in the industry. Stem cell therapy market report comprises of historic data, present market trends, market environment, technological innovation, upcoming technologies and the technical progress in the related industry. The data and information about Stem cell therapy industry are taken from reliable sources such as websites, annual reports of the companies, and journals, and then validated by the market experts. The Stem cell therapy report covers major manufacturers, suppliers, distributors, traders, customers, investors and major types, major applications.

The finest market research report is the one which is pertinent, unique, and creditable that employs proven tools and techniques to turn complex market insights into simpler version. Being the most suitable example of the above attributes, this Stem cell therapy report has been prepared by keeping in mind every market related aspect. Stem cell therapy market is supposed to grow during the forecast period due to growing demand at the end user level. According to this market report, new highs will take place in the market in 2019-2026. A market research carried out in this report assists in improving and enhancing the products so that future products offer more fulfilment to your valuable customers.

Get Sample Copy of this Report athttps://www.theinsightpartners.com/sample/TIPHE100000991/

MARKET INTRODUCTION

Stem cell therapy is a technique which uses stem cells for the treatment of various disorders. Stem cell therapy is capable of curing broad spectrum of disorders ranging from simple to life threatening. These stem cells are obtained from different sources, such as, adipose tissue, bone marrow, embryonic stem cell and cord blood among others. Stem cell therapy is enables to treat more than 70 disorders, including degenerative as well as neuromuscular disorders. The ability of a stem cell to renew itself helps in replacing the damaged areas in the human body.

Key Competitors In Stem Cell Therapy Market areMEDIPOST, PHARMICELL Co., Ltd, Holostem Terapie Avanzate S.r.l., Mesoblast Ltd, U.S. Stem Cell, Inc., BIOTIME, INC., Lonza, Caladrius, Takeda Pharmaceutical Company Limited, KOLON TISSUEGENE INC.

Market Segmentation:

By Type (Adult Stem Cell Therapy, Embryonic Stem Cell Therapy, Induced Pluripotent Stem Cell Therapy, Other Stem Cell Therapy);

By Treatment (Allogeneic, Autologous); Application (Muscoskeletal, Dermatology, Cardiology, Drug Discovery and Development, Other Applications)

By Geography North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. And 13 countries globally along with current trend and opportunities prevailing in the region.

Overview of the report

The study provides an in-depth analysis of the global market and current & future trends to elucidate imminent investment pockets.

Obtain the most up to date information available in all Market.

Information about key drivers, restraints, opportunities, and their impact analysis on the market size has been provided.

Identify growth segments and opportunities in the industry.

Assess your competitors refining portfolio and its evolution.

Click here to buy full report with all description:-https://www.theinsightpartners.com/buy/TIPHE100000991/

About Us:

The Insight Partnersis a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are committed to provide highest quality research and consulting services to our customers. We help our clients understand the key market trends, identify opportunities, and make informed decisions with our market research offerings at an affordable cost.

We understand syndicated reports may not meet precise research requirements of all our clients. We offer our clients multiple ways to customize research as per their specific needs and budget

Contact Us:

The Insight Partners,

Phone: +1-646-491-9876

Email:[emailprotected]

Read more:
Stem cell Therapy Market 2019-2027| Business Scope and Investment Analysis By MEDIPOST, PHARMICELL Co., Ltd, Holostem Terapie Avanzate Srl, Mesoblast...

Cutting Through the Headlines: Are Scientists Really Growing Sentient "Mini-brains"? – Technology Networks

Neuroscience 2019, the worlds biggest conference of brain science, finished just over a month ago. In the wake of some particularly inflammatory headlines, we take a closer look at whether claims that new model systems for studying the brain could produce sentience in a jar have any truth to them.

It must be a matter of some regret to researchers that, when they were first created a few years ago, the temptation to call the three-dimensional balls of neural tissue mini-brains proved too strong to resist.

At the Society for Neurosciences 2019 conference, the catchy, headline magnet term mini-brain had very much been taken out of the lexicon. In a press conference that we attended, the gathered scientific panel had obviously been encouraged to stick to a new term: brain organoid. More abstract than mini-brain, and certainly less likely to feature on a tabloid front cover.

As a session introducing the latest advances in organoid research drew to a close, the rebrand appeared to have worked. There had been no questions about Futurama-style talking heads in jars, or questions of existential cellular dread. So far. But by the end of the session, a dispute rose which highlighted some real doubts among researchers in the field, indicating that the topic of consciousness, let alone consciousness in a jar, was far from settled. But before we get to that, lets take a look at the science behind brain organoids.

The previous days plenary had gone very smoothly. A truly excellent talk by Harvard Stem Cell Institute (HSCI)s Paola Arlotta had shown the care and detail that had gone into organoid science.

Arlotta began her talk by outlining why researchers might consider making three-dimensional neuro-balls (my submission for what brain organoids should really be called) in the first place. Studying the brain is really hard. Its complexity is unrivaled by any other organ in the body and humans tend to object if you try and remove their brain to get a closer look.

As such, biomedical researchers have mainly focused on one of two approaches when attempting to model the incredible intricacy of the brain:

Clearly, neither route is perfect, and teams like Arlottas have been seeking a new model that could potentially take the best of both worlds and put them in one system. Brain organoids were meant to be that model. A lot of work has gone into enabling the creation of such a system, including huge steps in our tools for studying brain development. This requires handling data from more than just one cell type, as Arlotta explained in her lecture:

There are no individual subtypes that develop in isolation. They all develop together and it's really an orchestrated dance of many different cell types being generated. This is the complexity that we have always wanted to provide all at once. All cells, all genes, all stages, except we have never had the technology and methodology that would allow us to do that.

Forget a "brain in a jar". This image shows what pea-size brain organoids at 10 months old actually look like, grown in the Muotri lab at UCSD. Credit: Muotri Lab/UCTV

This changed a few years ago, when we invented amazing single-cell level genomics approaches that now allow us to sequence thousands, to hundreds of thousands, to millions of cells from any tissue any stage of any organism. Arlotta continues. This innovation, alongside computational methods, has permitted researchers to take a widescreen view of brain development.

For Arlottas team, capturing this global picture meant a lot of meticulous work: Basically, we set off to purify and refine, at a single cell level, every single cell of the developing somatosensory cortex, which we sampled every day in the mouse until about P1 [postnatal day 1] when the majority of the cells had been generated. The result: beautiful, detailed plots of the gene expression underlining the development of this region of the mouse brain.

With this information, a blueprint for how a brain organoid should develop, Arlottas team could then go on to create organoids.

The simplicity of this process is something that made even Arlotta do a double take at first. I was skeptical for many years, but then Yoshiki Sasai published what I think is a seminal experiment. Basically, what was shown is that if you take a 3D cluster of embryonic stem cells and you culture them in a dish, without adding much from the outside, these cells have the ability to self-organize and undergo self-morphogenesis to give rise to an optic-cup like structure. This cup has retinal and other cells of the mature eye, responds to light, and even forms morphological layers like an eye does. Sasais work, alongside that of Madeline Lancaster, formed the blueprint for future organoid work. It was published just seven years ago. This is a field advancing at a breakneck speed.

As such, its a field of great interest to the press and general public. To answer questions on her research, Arlotta joined UCSFs Arnold Kriegstein and Michael Nestor from the Hussman Institute for Autism for the next days panel discussion.

The main points from the panel were as follows:

The latter point, addressed by Kriegstein, seems pivotal to the future of this field. He presented results from single-cell RNA-seq (a technique that analyzes genetic material in base-by-base detail) scans of organoids and human brain tissue. The cell types are broadly similar to the ones you find in normally developing tissue, but the problem is that our genetic analysis is showing that they lack specificity, as though their identify is a bit confused, explained Kriegstein.

Images of brain tissue contrasted with organoids clearly show the reduced complexity of the model brains, with fewer cell types and a different developmental timeline. Kriegstein showed that the organoid cells are under a type of cellular stress that seems to limit their ability to mimic normal cells (although when the cells were transplanted into a mouse brain, creating a human-mouse chimera, the stress seemed to reduce). This is both an issue for the organoids potential as a model for brain disease, and for any claims that they might in any way become sentient in any human way.

Arlottas data had suggested that organoids were able to be kept in bioreactors, alive for up to four years. Could the simplified organoids simply not be old enough yet? This is not an adult brain that you make. Its not even a complete younger brain, its very primitive and reductive. There is a limit to what you can do in culture; they only grow to a certain size and they only make certain cells, said Arlotta.

This is a cross-section of a brain organoid, showing the initial formation of a cortical plate. Each color marks a different type of brain cell. Credit:Muotri Lab/UCTV

This point didnt come from a member of the press, but from another researcher. This was Elan Ohayon, co-founder of the San Diego-based Green Neuroscience Laboratory (GNL), who had been quoted in The Guardian in the days before SfN, singing from a very different hymnsheet from the panel. In that article, Ohayon had said, "If there's even a possibility of the organoid being sentient, we could be crossing that line. We don't want people doing research where there is potential for something to suffer." The GNL is also opposed to any captive animal experimentation. In the press event Ohayon professed at length, to a stony-faced response from the panel, why he believed they were underestimating the risk of an ethically dubious outcome from their research.

Ohayon finished by asking whether the researchers felt that the field should be put on hold until more was known about consciousness in the organoids. Nestor, in response, highlighted the lack of cytoarchitecture present to support the conditions needed for sentience, but he was cut off by a sharp retort from Ohayon. Thats incorrect. Actually thats my specialty, he began, before a stressed SfN staffer attempted to get him to sit down. Moving away from the microphone, Ohayon concluded, Its great that you are moving towards human-based research, the real concern is also this move towards chimera without thinking about sentience. You are underestimating where you are going, and its going to get there fast.

To say the least, Ohayons views seem quite at odds with that of the panel (the Green Neuroscience Laboratory did not immediately respond to request for comment for this interview). But, as with much in science, there is perhaps a truth to be found in between these two divergent positions.

Talking later to UC San Diego Professor Alysson Muotri, who has used brain organoids in his lab for years, we began to find evidence of where that midpoint might stand. He explains that he led a panel discussion on ethics in brain organoids, which you can watch below. The panel consisted of experts in both neuroscience and philosophy. Disagreements began with the basic definition of what consciousness is. Christof Koch, Chief Scientist and President of the Allen Brain Institute suggests that the cortex alone could be sufficient for consciousness, whilst Patricia Churchland, and Emerita Professor at UC San Diego suggested that other regions, like a brain stem or thalamus would be required. Other panel members, Muotri told me, argued that: You need a body, a brain connected to a body, otherwise there will be no consciousness coming from the tissue. How can we have a debate about creating a conscious being in a jar, if we dont really know what consciousness is in the first place?

What Muotri does suggest, in place of a halt to research, is a better effort to conduct studies in a more ethical way, similar to how scientists aim to conduct animal research. We don't treat animals badly just because they're for research. We try to give them a good lifestyle. So for the organoids it might be exactly the same thing. We just have to agree on how we should do it. I mean, what are the conditions that we need to keep them alive? How do we discard them? How many of them we should use to answer specific scientific questions? So these are the kinds of debate that we can start right now. But I just think it would be unfair to stop science.

So the potential of organoids, or brains-in-a-dish, or mini-brains, or whatever you want to call them, may be undeniable, but so is the potential of science to go faster than it intends. What scary headlines dont reflect is that scientists are well aware of both these things.

See original here:
Cutting Through the Headlines: Are Scientists Really Growing Sentient "Mini-brains"? - Technology Networks

Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 – Breaking News Updates

The Global Stem Cells Market report study includes an elaborative summary of the Stem Cells market that provides in-depth knowledge of various different segmentations. Stem Cells Market Research Report presents a detailed analysis based on the thorough research of the overall market, particularly on questions that border on the market size, growth scenario, potential opportunities, operation landscape, trend analysis, and competitive analysis of Stem Cells Market. The information includes the company profile, annual turnover, the types of products and services they provide, income generation, which provide direction to businesses to take important steps. Stem Cells delivers pin point analysis of varying competition dynamics and keeps ahead of Stem Cells competitors such as CCBC, Vcanbio, Boyalife, Beikebiotech.

View Sample Report @http://www.marketresearchstore.com/report/global-stem-cells-market-2019-by-manufacturers-regions-491303#RequestSample

The main objective of the Stem Cells report is to guide the user to understand the Stem Cells market in terms of its definition, classification, Stem Cells market potential, latest trends, and the challenges that the Stem Cells market is facing. In-depth researches and Stem Cells studies were done while preparing the Stem Cells report. The Stem Cells readers will find this report very beneficial in understanding the Stem Cells market in detailed. The aspects and information are represented in the Stem Cells report using figures, bar-graphs, pie diagrams, and other visual representations. This intensifies the Stem Cells pictorial representation and also helps in getting the Stem Cells industry facts much better.

.This research report consists of the worlds crucial region market share, size (volume), trends including the product profit, price, Value, production, capacity, capability utilization, supply, and demand and industry growth rate.

Geographically this report covers all the major manufacturers from India, China, the USA, the UK, and Japan. The present, past and forecast overview of the Stem Cells market is represented in this report.

The Study is segmented by following Product Type, Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other

Major applications/end-users industry are as follows Diseases Therapy, Healthcare

Stem Cells Market Report Highlights:

1)The report provides a detailed analysis of current and future market trends to identify the investment opportunities2) In-depth company profiles of key players and upcoming prominent players3) Global Stem Cells Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)4) Strategic recommendations in key business segments based on the market estimations5) To get the research methodologies those are being collected by Stem Cells driving individual organizations.

Research Parameter/ Research Methodology

Primary Research:

The primary sources involve the industry experts from the Global Stem Cells industry including the management organizations, processing organizations, analytics service providers of the industrys value chain. All primary sources were interviewed to gather and authenticate qualitative & quantitative information and determine future prospects.

In the extensive primary research process undertaken for this study, the primary sources industry experts such as CEOs, vice presidents, marketing director, technology & innovation directors, founders and related key executives from various key companies and organizations in the Global Stem Cells in the industry have been interviewed to obtain and verify both qualitative and quantitative aspects of this research study.

Secondary Research:

In Secondary research crucial information about the industry value chain, the total pool of key players, and application areas. It also assisted in market segmentation according to industry trends to the bottom-most level, geographical markets and key developments from both market and technology oriented perspectives.

Inquiry for Buying Report: http://www.marketresearchstore.com/report/global-stem-cells-market-2019-by-manufacturers-regions-491303#InquiryForBuying

Thanks for reading this article, you can also get individual chapter wise section or region wise report versions like North America, Europe or Asia. Also, If you have any special requirements, please let us know and we will offer you the report as you want.

Sorry! The Author has not filled his profile.

Continued here:
Global Stem Cells Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2025 - Breaking News Updates

Whats Happening: IDF Shabbat of Heroes, Sephardic Papers – Jewish Journal

FRI DEC 6

Zamru Friday NightShomrei Torah Synagogue holds Zamru Friday Night, a unique, musically rich kabbalat Shabbat service and dinner. Cantor Jackie Rafii and guitarist Daniel Raijman headline the event, Music to Move Your Soul. Guests bring their own kosher wine. 6-9 p.m. Dinner for members: $20 adults, $12 children 12 and under. General: $30 adults, $15 children. Shomrei Torah Synagogue, 7353 Valley Circle Blvd., West Hills. (818) 854-7650.

Middle East DiscussionGiven decades of conflict between the same rivals, punctuated by intermittent treaties, the Middle East is arguably the politically messiest region on earth. Jordan Reimer, policy analyst at the RAND Corp., helps to unpack the conflicts. A scholar who served under two White House administrations and the New York City Police Department, Reimer explains effects of the constant conflicts in the Middle East on Israel and the United States. 6:15 p.m. service. 7:30-9 p.m. lecture. Temple Isaiah, 10345 W. Pico Blvd. (310) 277-2772.

IKAR FeastIt is the first Friday of the month again, which means its time for IKARs monthly TRIBE Feast, a schmooze and groove at food-filled tables with Jewish and Jew-adjacent 20- and 30-somethings. RSVP requested so sufficient food is prepared. 6:30 p.m. Shabbat service. 7:45 p.m. TRIBE Feast. IKARs Event Space, 1729 S. La Cienega Blvd. (323) 634-1870.

Shabbat for WomenLev Eisha, a community of and for joyous Jewish women, celebrates a Shabbat infused with music and enlightened by teachings by Rabbi Toba August. She and cantorial soloist Cindy Paley lead Shabbat services. Everybody is welcome. 8:15 a.m. teaching. 9:30 a.m. service. Beth Shir Shalom, 1827 California Ave., Santa Monica. (310) 575-0985.

Max & Willys Last LaughWhen German comedian Max Ehrlich and his best friend, composer Willy Rosen, were caught in Holland in 1942 and sent to a concentration camp, the commandant recognized Ehrlich. He made an irresistible offer: Every Monday night before the train leaves for Auschwitz, Max and Willy will perform a cabaret. If they are funny, they will perform it the following week. If not, they will be put on the train. The performers carried on for 18 months before finally being sent to Auschwitz. Tonight and Sunday afternoon, Temple Emanuel of Beverly Hills presents a staged reading with live music of Max and Willys Last Laugh. Proceeds benefit Temple Emanuel of Beverly Hills. 8 p.m. tonight, 5 p.m. Sunday. $100 reserved seats, $36 general admission, $18 students. James Bridges Theater at UCLA, 235 Charles E. Young Drive East. (310) 825-6792.

Beth Am Film NightAfter Shabbat ends, Temple Beth Am resumes its film series with Laces, the story of a special needs sons complex relationship with the aging father who abandoned him when he was a child. Film buff Michael Berlin leads a post-film discussion. Snacks served. 7 p.m. $12. Temple Beth Am, 1039 S. La Cienega Blvd. (310) 652-7353.

Shulem Lemmer

Our IDF HeroesAfter a Shabbat of Heroes at Pico-Robertson synagogues Adas Torah, Beth Jacob, Bnai David-Judea and Young Israel of Century City, a meet and greet with heroes of the Israel Defense Forces (IDF) takes place at The Mark. Ezer Mizion, the worlds largest Jewish bone marrow registry, organizes this gathering, highlighting how as of August, 2,000 IDF soldiers have donated their stem cells to 2,000 patients around the world. The evening features musician Shulem Lemmer performing during Havdalah and former Israeli Chief Rabbi Yisrael Meir Lau bringing greetings from the Jewish state. Israeli wines and food served. Adults only. RSVP required. 7:30 p.m. The Mark, W. 9320 Pico Blvd. (310) 247-2266.

Sarah Abrevaya Stein

Family Papers: A Sephardic JourneyFor centuries from the Greek port city of Salonica, the large Levy family of editors and publishers reported how the ever-changing state of modernity affected Sephardic Jews across the Ottoman Empire, including how 20th-century wars altered the borders around them. Historian Sarah Abrevaya Stein shares the true story of a frayed family that has been preserved through their letters. She discusses her award-winning book, Family Papers: A Sephardic Journey Through the Twentieth Century, with race and gender scholar Brenda E. Stevenson. 2 p.m. Free. Skirball Cultural Center, 2701 N. Sepulveda Blvd. (310) 440-4500.

Community Service DayAttention all people who seek to make a difference immediately: The Jewish Federation of Greater Los Angeles Community Service Day lasts all day and is a partnership between Federation and social service organizations working to make life better for their neighbors. Free. Prior registration required. For more information, email volunteer@jewishla.org.

The Golden Gelt RoomJoin the Congregation Kol Ami community in The Golden Gelt Room, for an afternoon of comedy, casino games and pre-Hanukkah celebration. Comedian Liz Glazer performs. Mingle, nosh, drink, play and laugh with Kol Amis inclusive community. 4-6:30 p.m. $100. Congregation Kol Ami, 1200 N. La Brea Ave., West Hollywood. (323) 606-0996..

Hanukkah Angels Gift-Wrapping EventThere still is time to become a Hanukkah Angel in Kehillat Maaravs community mitzvah program. Purchase a gift of any amount for one of 10 Chai Lifeline children with life-threatening illnesses, then bring it to the synagogue starting at 9 a.m. and join the synagogues religious school students in gift-wrapping from 11:30 a.m.-12:30 p.m. Latkes and sufganiyot served. To learn about each childs wish list or to become a Hanukkah Angel, contact Rose or Sharone Weizman at eddirector@km-synagogue.org. 1715 21st St., Santa Monica. (310) 829-0566.

Jewish ID Hanukkah PartyEven though Hanukkah doesnt start for two weeks, Jewish Big Brothers Big Sisters of Los Angeles (JBBBSLA) starts early. Bring the children to Stephen Wise Temple for a huge Hanukkah celebration co-organized by JBBBSLA and Kibbutz Bob Waldorf. Ideal for all ages. Candlemaking, Israeli dancing, dreidel games and camp activities highlight the event. If the $5 per person charge is too expensive (children 3-and-under are admitted free), contact Sofia Varona at (323) 456-1162 or sofia@campbobwaldorf.org. 4 p.m. $5. Stephen Wise Temple, 15500 Stephen S. Wise Drive.

BYTHAX Gospel Choir

Hanukkah and Christmas ConcertWilshire Boulevard Temple stages a performance of peace, love and harmony. The congregations Let There Be Light concert of Hanukkah and Christmas melodies, co-organized by the Faithful Central Bible Church, features performers Dr. Dee, the BYTHAX Gospel Choir, Cantor Don Gurney and the Wilshire Boulevard Temple Adult Choir. Sufganiyot and holiday cookies are served after the concert. 4 p.m. Free. RSVP required. Wilshire Boulevard Temple, 3663 Wilshire Blvd. (213) 388-2401.

Lets Talk About ReligionIn the latest round of American Jewish Universitys (AJU) discussion series Lets Talk About Religion: Jews, Christians and Muslims in Conversation, a Jew and a Muslim examine rival and converging views on Is Life Sacred? Tonights topics are medical ethics, abortion and end-of-life issues, with Rabbi Elliot Dorff, rector and professor in philosophy at AJU, in discussion with Dr. Sana Khan, chairman and founder of theAiM Radiology Medical Group. 7:30-9 p.m. $10. American Jewish University, Alan Shapiro Memorial Synagogue, 15600 Mulholland Drive. (310) 440-1572.

The Holocaust and the Danish ExceptionThe Los Angeles Museum of the Holocaust holds a book signing and artists reception with acclaimed photographer Judy Glickman Lauder. Her photos are on exhibit in Beyond the Shadows: The Holocaust and the Danish Exception. Lauder, a Bay Area native, has been photographing Holocaust sites since the 1980s. She talks about her experiences. 7-8:30 p.m. $10 suggested donation. Los Angeles Museum of the Holocaust in Pan Pacific Park, 100 The Grove Drive. (323) 651-3704.

Have an event coming up? Send your information two weeks prior to the event to ryant@jewishjournal.com for consideration. For groups staging an event that requires an RSVP, please submit details about the event the week before the RSVP deadline.

Excerpt from:
Whats Happening: IDF Shabbat of Heroes, Sephardic Papers - Jewish Journal

Marine Coatings Market is Anticipated to Register a Value of XX Million by the end of 2017 – 2025 – Markets Gazette 24

Detailed Study on the Marine Coatings Market

The latest report published by Transparency Market Research on the global Marine Coatings market reveals that the market is expected to grow at a CAGR of ~XX% during the forecast period (2019-2029) and reach a value of ~US$ XX by the end of 2019. Further, by leveraging the data in the report, investors, established players, emerging market players, and stakeholders can develop effective business strategies to cement their position in the global Marine Coatings market.

The report ponders over the micro and macro-economic factors that are expected to shape the growth of the Marine Coatings market in the upcoming decade. The report includes a SWOT analysis of some prominent players in the Marine Coatings market wherein the business prospects of each player are discussed in detail.

Concessions for new customers! Offer expires soon!

Request For Discount On This Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=D&rep_id=902

Vital Market Information Included in the Report:

The report resolves the following doubts related to the Marine Coatings market:

Request Sample Report @ https://www.transparencymarketresearch.co/sample/sample.php?flag=B&rep_id=902

Marine Coatings Market Bifurcation

The Marine Coatings market is bifurcated into different sections to provide a clear understanding of the various aspects of the market. The growth potential, market share, size, and prospects of each segment and sub-segment is depicted in the report.

segmentation study, geographical analysis, vendor landscape study, and other aspects that could prove to be significant for ensuring a strong growth in the global stem cells market.

Global Stem Cells Market: Trends and Opportunities

The world stem cells market is predicted to attain favorable growth prospects on the back of the positive impact caused by swelling investments from biopharmaceutical and pharmaceutical companies for conducting stem cell research. Increasing incidence of chronic diseases could be another powerful factor augmenting the demand in the market. For the coming years, market growth is anticipated to be cemented with the rise of increasing research and development, high-quality stem cell banking facilities, and rising count of stem cell donors.

Amongst all major types, adult stem cells are projected to secure a high demand in the near future as they could multiply into scores of specialized cells capable of repairing tissue damage and lowering the risks of rejection. Budding segments such as induced pluripotent stem cells could also offer rewarding prospects in the market with the help of their unique traits and advantages.

Global Stem Cells Market: Geographical Analysis

The international stem cells market is foreseen to testify the dominance of North America which has always been at the forefront of the adoption of latest technologies. Besides its impressive technological progress, the region could improve its growth while riding on the increasing prevalence of target chronic disorders, high economic growth, and massive investments in the industry. As a result, the regional market is forecast to showcase a colossal growth in the coming years.

Treading on the heels of North America, Europe could also provide lucrative growth opportunities in the international stem cells market due to factors such as medical tourism. An increasing number of U.S. and Canada patients have been witnessed to travel to Europe for taking treatments made available at economical costs. Asia Pacific is envisioned to exhibit a relatively slower growth in the market due to various reasons.

Global Stem Cells Market: Companies Mentioned

With a view to expand their presence as well as their portfolios when operating in the worldwide stem cells market, players are foretold to work out strategic partnerships and collaborations with pharmaceutical firms. Moreover, they could look to raise funds with the help of overseas organizations to introduce new stem cell-based therapies in the market. Some of the leading companies in the market could be Cellular Engineering Technologies Inc., Astellas Pharma Inc., and STEMCELL Technologies Inc.

Global Stem Cells Market by Product

Global Stem Cells Market by Source

Global Stem Cells Market by Application

Global Stem Cells Market by End User

Global Stem Cells Market by Geography

RequestTOC For ThisReport @ https://www.transparencymarketresearch.co/sample/sample.php?flag=T&rep_id=902

What Sets TMR Apart From the Rest?

See the rest here:
Marine Coatings Market is Anticipated to Register a Value of XX Million by the end of 2017 - 2025 - Markets Gazette 24

‘I was given a terminal diagnosis and then a new therapy cured my leukaemia’ – The Telegraph

When my GP assessed me, he just couldnt explain it, she recalls. Referred to Heartlands Hospital, Sophie was given a blood test. By then I was sitting on a ward. Everyone else was 60-plus and had leukaemia and I thought Well, I havent got that. I was 20.

Finally she was called into a tiny consultation room. The doctor had his head in his hands. I literally dont believe it, he told Sophie. Its leukaemia.

In the blink of an eye, Sophies old life ended. She called her parents (You better hurry up because its not good) and was immediately admitted to hospital. Diagnosed on Friday, treatment began on Monday. So swiftly did it begin that there was no time to think about side-effects. No time for saving fertility or anything like that, she recalls matter-of-factly, her bright Chelmsley Wood accent belying the astonishing gravity of her experience.

Her hair started falling out. She had Acute lymphoblastic leukaemia (ALL), one of the four types of life-threatening, acute leukaemia. (Other non-curable but largely non-fatal forms of the disease are known as chronic leukaemia.)Of the 10,000 or so people diagnosed with leukaemia in the UK each year, about 350 have ALL.

There are no official statistics but estimates suggest that five-year ALL survival rates for 15-24 year-olds are about 70pc. One of the key factors affecting that survival, however, is early diagnosis. To put it bluntly, if any cancer has progressed so far that patients walk straight in to A&E, bypassing their GP, it bodes poorly.

Visit link:
'I was given a terminal diagnosis and then a new therapy cured my leukaemia' - The Telegraph

Stem Cell Therapy Market Robust pace of Industry during 2017-2025 – News Description

Stem Cell Therapy Market: Snapshot

Of late, there has been an increasing awareness regarding the therapeutic potential of stem cells for management of diseases which is boosting the growth of the stem cell therapy market. The development of advanced genome based cell analysis techniques, identification of new stem cell lines, increasing investments in research and development as well as infrastructure development for the processing and banking of stem cell are encouraging the growth of the global stem cell therapy market.

To know Untapped Opportunities in the Market CLICK HERE NOW

One of the key factors boosting the growth of this market is the limitations of traditional organ transplantation such as the risk of infection, rejection, and immunosuppression risk. Another drawback of conventional organ transplantation is that doctors have to depend on organ donors completely. All these issues can be eliminated, by the application of stem cell therapy. Another factor which is helping the growth in this market is the growing pipeline and development of drugs for emerging applications. Increased research studies aiming to widen the scope of stem cell will also fuel the growth of the market. Scientists are constantly engaged in trying to find out novel methods for creating human stem cells in response to the growing demand for stem cell production to be used for disease management.

It is estimated that the dermatology application will contribute significantly the growth of the global stem cell therapy market. This is because stem cell therapy can help decrease the after effects of general treatments for burns such as infections, scars, and adhesion. The increasing number of patients suffering from diabetes and growing cases of trauma surgery will fuel the adoption of stem cell therapy in the dermatology segment.

Global Stem Cell Therapy Market: Overview

Also called regenerative medicine, stem cell therapy encourages the reparative response of damaged, diseased, or dysfunctional tissue via the use of stem cells and their derivatives. Replacing the practice of organ transplantations, stem cell therapies have eliminated the dependence on availability of donors. Bone marrow transplant is perhaps the most commonly employed stem cell therapy.

Osteoarthritis, cerebral palsy, heart failure, multiple sclerosis and even hearing loss could be treated using stem cell therapies. Doctors have successfully performed stem cell transplants that significantly aid patients fight cancers such as leukemia and other blood-related diseases.

Get Discount on Latest Report @ CLICK HERE NOW

Global Stem Cell Therapy Market: Key Trends

The key factors influencing the growth of the global stem cell therapy market are increasing funds in the development of new stem lines, the advent of advanced genomic procedures used in stem cell analysis, and greater emphasis on human embryonic stem cells. As the traditional organ transplantations are associated with limitations such as infection, rejection, and immunosuppression along with high reliance on organ donors, the demand for stem cell therapy is likely to soar. The growing deployment of stem cells in the treatment of wounds and damaged skin, scarring, and grafts is another prominent catalyst of the market.

On the contrary, inadequate infrastructural facilities coupled with ethical issues related to embryonic stem cells might impede the growth of the market. However, the ongoing research for the manipulation of stem cells from cord blood cells, bone marrow, and skin for the treatment of ailments including cardiovascular and diabetes will open up new doors for the advancement of the market.

Global Stem Cell Therapy Market: Market Potential

A number of new studies, research projects, and development of novel therapies have come forth in the global market for stem cell therapy. Several of these treatments are in the pipeline, while many others have received approvals by regulatory bodies.

In March 2017, Belgian biotech company TiGenix announced that its cardiac stem cell therapy, AlloCSC-01 has successfully reached its phase I/II with positive results. Subsequently, it has been approved by the U.S. FDA. If this therapy is well- received by the market, nearly 1.9 million AMI patients could be treated through this stem cell therapy.

Another significant development is the granting of a patent to Israel-based Kadimastem Ltd. for its novel stem-cell based technology to be used in the treatment of multiple sclerosis (MS) and other similar conditions of the nervous system. The companys technology used for producing supporting cells in the central nervous system, taken from human stem cells such as myelin-producing cells is also covered in the patent.

Global Stem Cell Therapy Market: Regional Outlook

The global market for stem cell therapy can be segmented into Asia Pacific, North America, Latin America, Europe, and the Middle East and Africa. North America emerged as the leading regional market, triggered by the rising incidence of chronic health conditions and government support. Europe also displays significant growth potential, as the benefits of this therapy are increasingly acknowledged.

Asia Pacific is slated for maximum growth, thanks to the massive patient pool, bulk of investments in stem cell therapy projects, and the increasing recognition of growth opportunities in countries such as China, Japan, and India by the leading market players.

Request TOC of the Report for more Industry Insights @CLICK HERE NOW

Global Stem Cell Therapy Market: Competitive Analysis

Several firms are adopting strategies such as mergers and acquisitions, collaborations, and partnerships, apart from product development with a view to attain a strong foothold in the global market for stem cell therapy.

Some of the major companies operating in the global market for stem cell therapy are RTI Surgical, Inc., MEDIPOST Co., Ltd., Osiris Therapeutics, Inc., NuVasive, Inc., Pharmicell Co., Ltd., Anterogen Co., Ltd., JCR Pharmaceuticals Co., Ltd., and Holostem Terapie Avanzate S.r.l.

About TMR Research:

TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in todays supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.

Contact:

TMR Research,

3739 Balboa St # 1097,

San Francisco, CA 94121

United States

Tel: +1-415-520-1050

The rest is here:
Stem Cell Therapy Market Robust pace of Industry during 2017-2025 - News Description

A #ReUp of 2019: The year when gene therapy, DNA modifications came of age & saved lives – Economic Times

In the summer, a mother in Nashville with a seemingly incurable genetic disorder finally found an end to her suffering -- by editing her genome.

Victoria Gray's recovery from sickle cell disease, which had caused her painful seizures, came in a year of breakthroughs in one of the hottest areas of medical research -- gene therapy.

"I have hoped for a cure since I was about 11," the 34-year-old told AFP in an email.

"Since I received the new cells, I have been able to enjoy more time with my family without worrying about pain or an out-of-the-blue emergency."

Over several weeks, Gray's blood was drawn so doctors could get to the cause of her illness -- stem cells from her bone marrow that were making deformed red blood cells.

The stem cells were sent to a Scottish laboratory, where their DNA was modified using Crispr/Cas9 -- pronounced "Crisper" -- a new tool informally known as molecular "scissors."

The genetically edited cells were transfused back into Gray's veins and bone marrow. A month later, she was producing normal blood cells.

Medics warn that caution is necessary but, theoretically, she has been cured.

"This is one patient. This is early results. We need to see how it works out in other patients," said her doctor, Haydar Frangoul, at the Sarah Cannon Research Institute in Nashville.

"But these results are really exciting."

In Germany, a 19-year-old woman was treated with a similar method for a different blood disease, beta thalassemia. She had previously needed 16 blood transfusions per year.

Nine months later, she is completely free of that burden.

For decades, the DNA of living organisms such as corn and salmon has been modified.

But Crispr, invented in 2012, made gene editing more widely accessible. It is much simpler than preceding technology, cheaper and easy to use in small labs.

The technique has given new impetus to the perennial debate over the wisdom of humanity manipulating life itself.

"It's all developing very quickly," said French geneticist Emmanuelle Charpentier, one of Crispr's inventors and the cofounder of Crispr Therapeutics, the biotech company conducting the clinical trials involving Gray and the German patient.

Crispr is the latest breakthrough in a year of great strides in gene therapy, a medical adventure started three decades ago, when the first TV telethons were raising money for children with muscular dystrophy.

Scientists practising the technique insert a normal gene into cells containing a defective gene.

It does the work the original could not -- such as making normal red blood cells, in Victoria's case, or making tumor-killing super white blood cells for a cancer patient.

Crispr goes even further: instead of adding a gene, the tool edits the genome itself.

After decades of research and clinical trials on a genetic fix to genetic disorders, 2019 saw a historic milestone: approval to bring to market the first gene therapies for a neuromuscular disease in the US and a blood disease in the European Union.

They join several other gene therapies -- bringing the total to eight -- approved in recent years to treat certain cancers and an inherited blindness.

Serge Braun, the scientific director of the French Muscular Dystrophy Association, sees 2019 as a turning point that will lead to a medical revolution.

"Twenty-five, 30 years, that's the time it had to take," he told AFP from Paris.

"It took a generation for gene therapy to become a reality. Now, it's only going to go faster."

Just outside Washington, at the National Institutes of Health (NIH), researchers are also celebrating a "breakthrough period."

"We have hit an inflection point," said Carrie Wolinetz, NIH's associate director for science policy.

These therapies are exorbitantly expensive, however, costing up to $2 million -- meaning patients face grueling negotiations with their insurance companies.

They also involve a complex regimen of procedures that are only available in wealthy countries.

Gray spent months in hospital getting blood drawn, undergoing chemotherapy, having edited stem cells reintroduced via transfusion -- and fighting a general infection.

"You cannot do this in a community hospital close to home," said her doctor.

However, the number of approved gene therapies will increase to about 40 by 2022, according to MIT researchers.

They will mostly target cancers and diseases that affect muscles, the eyes and the nervous system.

Another problem with Crispr is that its relative simplicity has triggered the imaginations of rogue practitioners who don't necessarily share the medical ethics of Western medicine.

Last year in China, scientist He Jiankui triggered an international scandal -- and his excommunication from the scientific community -- when he used Crispr to create what he called the first gene-edited humans.

The biophysicist said he had altered the DNA of human embryos that became twin girls Lulu and Nana.

His goal was to create a mutation that would prevent the girls from contracting HIV, even though there was no specific reason to put them through the process.

"That technology is not safe," said Kiran Musunuru, a genetics professor at the University of Pennsylvania, explaining that the Crispr "scissors" often cut next to the targeted gene, causing unexpected mutations.

"It's very easy to do if you don't care about the consequences," Musunuru added.

Despite the ethical pitfalls, restraint seems mainly to have prevailed so far.

The community is keeping a close eye on Russia, where biologist Denis Rebrikov has said he wants to use Crispr to help deaf parents have children without the disability.

There is also the temptation to genetically edit entire animal species -- malaria-causing mosquitoes in Burkina Faso or mice hosting ticks that carry Lyme disease in the US.

The researchers in charge of those projects are advancing carefully, however, fully aware of the unpredictability of chain reactions on the ecosystem.

6 Nov, 2019

6 Nov, 2019

6 Nov, 2019

6 Nov, 2019

6 Nov, 2019

Charpentier doesn't believe in the more dystopian scenarios predicted for gene therapy, including American "biohackers" injecting themselves with Crispr technology bought online.

"Not everyone is a biologist or scientist," she said.

And the possibility of military hijacking to create soldier-killing viruses or bacteria that would ravage enemies' crops?

Charpentier thinks that technology generally tends to be used for the better.

"I'm a bacteriologist -- we've been talking about bioterrorism for years," she said. "Nothing has ever happened."

Continued here:
A #ReUp of 2019: The year when gene therapy, DNA modifications came of age & saved lives - Economic Times

Kyoto University Seeking To Use Stem Cells On Knee Treatment – Anti Aging News

Kyoto University has asked the government of Japan for approval to conduct a human clinical trial involving transplanting cartilage made from induced pluripotent stem cells as an approach to treat damaged knee joints.

Led by Professor Noriyuki Tsumaki the research team will be culturing iPS cells to create cartilage tissue which will be used to transplant into knees; according to the University the team submitted the study plan to the health ministry on November 7, 2019 for review by its special panel.

Their treatment approach has already been tested in animal studies where it was found to be effective and shown to carry a low risk of rejection, cancerization, and fibrosis reaction, according to the Kyoto research team.

Their plan which includes its safety was approved in October by a University board, which is hoped to help treat patients with degenerated or damaged cartilage due to injuries or illness. Cartilage tissue covers joint bones and absorbs shock, joints are not able to move smoothly if the cartilage is damaged or if it turns fibrous with age.

The Kyoto team hopes that this treatment will be an improvement on current methods in which cartilage tissue is transplanted as it is hard to acquire tissues, and the transplanted tissues often tend to turn fibrous to help effectively treat damaged knee joints.

Follow this link:
Kyoto University Seeking To Use Stem Cells On Knee Treatment - Anti Aging News